Competing roads to larynx preservation

Journal of Clinical Oncology

Volumn 31, Issue 7, 2013, Pages 833-836

  Vokes, Everett E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADD ON THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMORADIOTHERAPY; DRUG EFFICACY; EDITORIAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LARYNGECTOMY; LARYNX; LARYNX CANCER; MULTIPLE CYCLE TREATMENT; ORGAN PRESERVATION; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DEGLUTITION; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LARYNGEAL NEOPLASMS; MALE; ORGAN SPARING TREATMENTS; SPEECH;

EID: 84875743953     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.8976     Document Type: Editorial

References (18)

1. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1690, 1991.
2. Lefebvre JL, Chevalier D, Luboinski B, et al: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88:890-899, 1996. (Pubitemid 26230640)
3. Forastiere AA, Goepfert H, Maor M, et al: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091-2098, 2003. (Pubitemid 37464533)
4. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007. (Pubitemid 350005151)
5. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007. (Pubitemid 350005152)
6. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-506, 2009.
7. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21-28, 2010.
8. Ang KK, Zhang QE, Rosenthal DI, et al: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:360s, 2011 (suppl; abstr 5500).
9. Mell LK, Dignam JJ, Salama JK, et al: Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol 28:15-20, 2010.
10. Forastiere AA, Zhang Q, Weber RS, et al: Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845-852, 2013.
11. Lefebvre JL, Ang KK, Larynx Preservation Consensus Panel: Larynx preservation clinical trial design: Key issues and recommendations-A consensus panel summary. Int J Radiat Oncol Biol Phys 73:1293-1303, 2009.
12. List MA, Stracks J, Colangelo L, et al: How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol 18:877-884, 2000. (Pubitemid 30106620)
13. Brockstein B, Haraf DJ, Rademaker AW, et al: Patterns of failure, prognostic factors and survival in loco regionally advanced head and neck cancer treated with concomitant chemo radiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179-1186, 2004. (Pubitemid 39199304)
14. Lefebvre JL, Pointreau Y, Rolland F, et al: Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J Clin Oncol 31:853-859, 2013.
15. Haddad RI, Rabinowits G, Tishler RB, et al: The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). J Clin Oncol 30:356s, 2012 (suppl; abstr 5501).
16. Cohen EEW, Karrison T, Kocherginsky M, et al: DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:356s, 2012 (suppl; abstr 5500).
17. Agrawal N, Frederick MJ, Pickering CR, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154-1157, 2011.
18. Stransky N, Egloff AM, Tward AD, et al: The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160, 2011.